Through the new DTP platform, Novartis will make Cosentyx available to patients at a price that reflects the average savings typically retained by insurers and pharmacy benefit managers
European approval is based on robust Phase III data showing Cosentyx provided rapid symptom relief from as early as Week 4, with response rates continuing to improve up to 1 year1,3-5
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
Positive opinion could expand the role of Cosentyx (secukinumab) in reducing flare risk in pediatric enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) patients in the EU
Cosentyx is a proven treatment, supported by long-term five-year sustained efficacy and safety data across several inflammatory conditions and with more than 500,000 patients treated worldwide since launch
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Transformation to pure-play Innovative Medicines company nears completion
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
Subscribe To Our Newsletter & Stay Updated
